Ascendis Pharma A/S Price & Performance (ASND)

Ascendis Pharma shares climbed 4.4% to $165.05, with analysts from major banks raising price targets to as high as $260. The consensus rating stands at 'Moderate Buy,' reflecting optimism around the company’s rare disease therapies and recent earnings beat. Insider ownership remains high, signaling confidence in future growth.12

Ascendis Pharma has submitted a New Drug Application to the FDA for TransCon CNP, targeting children with achondroplasia. The application is backed by robust clinical trial data showing improved growth and reduced health burdens. The company plans European submissions later this year, further expanding its rare disease portfolio.34

Short interest in Ascendis Pharma dropped by 1.6%, indicating a shift toward more positive investor sentiment. Despite the company’s negative P/E ratio, strong insider ownership and increased news coverage suggest growing market confidence as the firm pursues regulatory and commercial milestones in rare disease treatment.15